Effects of dimerization on the structure and biological activity of antimicrobial peptide Ctx-Ha

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3004-3010

  Lorenzon E N ^a   Cespedes, G F ^a   Vicente, E F ^a   Nogueira, L G ^a   Bauab, T M ^a   Castro, M S ^b   Cilli, E M ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYFLUORESCEIN; CTX HA; POLYPEPTIDE ANTIBIOTIC AGENT; SPHINGOMYELIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CANDIDA ALBICANS; CONTROLLED STUDY; DIMERIZATION; DRUG PENETRATION; DRUG SYNTHESIS; ESCHERICHIA COLI; HEMOLYSIS; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS; STAPHYLOCOCCUS AUREUS;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELLS, CULTURED; HEMOLYSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; PROTEIN MULTIMERIZATION; SOLID-PHASE SYNTHESIS TECHNIQUES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84861170375     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06262-11     Document Type: Article

References (45)

1. Benincasa M, et al. 2009. Activity of antimicrobial peptides in the presence of polysaccharides produced by pulmonary pathogens. J. Pept. Sci. 9:595-600.
2. Casallanovo F, et al. 2006. Model peptides mimic the structure and function of the N-terminus of the pore-forming toxin sticholysin. II. Biopolymers 84:169-180.
3. Castro MS, et al. 2009. Hylin a1, the first cytolytic peptide isolated from the arboreal South American frog Hypsiboas albopunctatus ("spotted treefrog"). Peptides 30:291-296.
4. Cespedes GF, et al. Mechanism of action and relationship between structure and biological activity of Ctx-Ha, a new ceratotoxin-like peptide from Hypsiboas albopunctatus. Protein Pept. Lett. 19:595-602.
5. Chen YX, et al. 2005. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J. Biol. Chem. 280:12316-12329.
6. Chen YX, et al. 2007. Role of peptide hydrophobicity in the mechanism of action of alpha-helical antimicrobial peptides. Antimicrob. Agents Chemother. 51:1398-1406.
7. Cilli EM, et al. 2007. Correlations between differences in amino-terminal sequences and different hemolytic activity of sticholysins. Toxicon 50:1201-1204. (Pubitemid 350087175)
8. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, 6th ed. Document M7-A6. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for yeast; approved standards, 6th ed. Document M27-A2. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Crusca E, et al. 2011. Influence of N-terminus modifications on the biological activity, membrane interaction, and secondary structure of the antimicrobial peptide Hylin-a1. Biopolymers 96:41-48.
11. Dempsey CE, Ueno S, Avison MB. 2003. Enhanced membrane permeabilization and antibacterial activity of a disulfide-dimerized magainin analogue. Biochemistry 42:402-409. (Pubitemid 36105758)
12. Eckert R, et al. 2006. Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob. Agents Chemother. 50:1480-1488.
13. Falciani C, et al. 2007. Molecular basis of branched peptides resistance to enzyme proteolysis. Chem. Biol. Drug Des. 69:216-221. (Pubitemid 46608454)
14. Grant GA. 2002. Synthetic peptides: a user's guide, 2nd ed. Oxford University Press, New York, NY.
15. Guani-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Teran LM. 2010. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin. Immunol. 135:1-11.
16. Hara T, et al. 2001. Effects of peptide dimerization on pore formation: antiparallel disulfide-dimerized magainin 2 analogue. Biopolymers 58:437-446. (Pubitemid 32187679)
17. Hornef MW, Putsep K, Karlsson J, Refai E, Andersson M. 2004. Increased diversity of intestinal antimicrobial peptides by covalent dimer formation. Nat. Immunol. 5:836-843. (Pubitemid 39172977)
18. Huang Y, Huang J, Chen Y. 2010. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 1:143-152.
19. Janin YL. 2003. Peptides with anticancer use or potential. Amino Acids 25:1-40. (Pubitemid 36934517)
20. Jiang Z, Vasil AI, Gera L, Vasil ML, Hodges RS. 2011. Rational design of alpha-helical antimicrobial peptides to target gram-negative pathogens, Acinetobacter baumannii and Pseudomonas aeruginosa: utilization of charge, 'specificity determinants', total hydrophobicity, hydrophobe type and location as design parameters to improve the therapeutic ratio. Chem. Biol. Drug Des. 77:225-240.
21. Johnsen L, Fimland G, Eijsink V, Nissen-Meyer J. 2000. Engineering increased stability in the antimicrobial peptide pediocin PA-1. Appl. Environ. Microbiol. 66:4798.
22. Jubilut GN, et al. 2001. Evaluation of the trifluoromethanosulfonic acid/trifluoroacetic acid/thioanisole cleavage procedure for application in solid-phase peptide synthesis. Chem. Pharm. Bull. 49:1089-1092. (Pubitemid 32847513)
23. Lee JY, et al. 2008. Salt-resistant homodimeric bactenecin, a cathelicidin-derived antimicrobial peptide. FEBS J. 275:3911-3920. (Pubitemid 351990953)
24. Libério MS, et al. 2011. Anti-proliferative and cytotoxic activity of pentadactylin isolated from Leptodactylus labyrinthicus on melanoma cells. Amino Acids 40:51-59.
25. Liu S, Zhou L, Lakshminarayanan R, Beuerman R. 2010. Multivalent antimicrobial peptides as therapeutics: design principles and structural diversities. Int. J. Pept. Protein Res. 16:199-213.
26. Liu Z, et al. 2006. Multivalent antimicrobial peptides from a reactive polymer scaffold. J. Med. Chem. 49:3436-3439. (Pubitemid 43902448)
27. Matsuzaki K. 2009. Control of cell selectivity of antimicrobial peptides. Biochim. Biophys. Acta 1788:1687-1692.
28. Melo MN, Ferre R, Castanho MARB. 2009. Antimicrobial peptides: linking partition, activity and high membrane-bound concentrations. Nat. Rev. Microbiol. 7:245-250.
29. Nijssen S, et al. 2010. Effects of reducing beta-lactam antibiotic pressure on intestinal colonization of antibiotic-resistant gram-negative bacteria. Intensive Care Med. 36:512-519.
30. Peters BM, Shirtliff ME, Jabra-Rizk MA. 2010. Antimicrobial peptides: primeval molecules or future drugs? PLoS Pathog. 6:e1001067.
31. Pini A, et al. 2010. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J. 24:1015-1022.
32. Pini A, et al. 2005. Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 49:2665-2672. (Pubitemid 40917576)
33. Sengupta D, Leontiadou H, Mark AE, Marrink SJ. 2008. Toroidal pores formed by antimicrobial peptides show significant disorder. Biochim. Biophys. Acta 1778:2308-2317.
34. Strömstedt AA, Pasupuleti M, Schmidtchen A, Malmsten M. 2009. Evaluation of strategies for improving proteolytic resistance of antimicrobial peptides by using variants of EFK17, an internal segment of LL-37. Antimicrob. Agents Chemother. 53:593-602.
35. Tam JP. 1988. Synthetic peptide vaccine design-synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U. S. A. 85:5409-5413.
36. Taylor K, et al. 2007. Covalent dimer species of beta-defensin Defr1 display potent antimicrobial activity against multidrug-resistant bacterial pathogens. Antimicrob. Agents Chemother. 51:1719-1724. (Pubitemid 46744150)
37. Tsai PW, Yang CY, Chang HT, Lan CY. 2011. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS One 6:e17755.
38. Wang P, et al. 2010. Cell selectivity and anti-inflammatory activity of a Leu/Lys-rich alpha-helical model antimicrobial peptide and its diastereomeric peptides. Peptides 31:1251-1261.
39. Welling MM, Brouwer CP, Wvan't Hof Veerman EC, Amerongen AV. 2007. Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo. Antimicrob. Agents Chemother. 51:3416-3419. (Pubitemid 350067569)
40. Yang ST, Kim JI, Shin SY. 2009. Effect of dimerization of a beta-turn antimicrobial peptide, PST13-RK, on antimicrobial activity and mammalian cell toxicity. Biotechnol. Lett. 31:233-237.
41. Yount NY, Yeaman MR. 2005. Immunocontinuum: perspectives in antimicrobial peptide mechanisms of action and resistance. Protein Pept. Lett. 12:49-67. (Pubitemid 40068360)
42. Zaragoza A, et al. 2010. Hemolytic activity of a bacterial trehalose lipid biosurfactant produced by Rhodococcus sp.: evidence for a colloidosmotic mechanism. Langmuir 26:8567-8572.
43. Zhu WL, Nan YH, Hahm KS, Shin SY. 2007. Cell selectivity of an antimicrobial peptide melittin diastereomer with D-amino acid in the leucine zipper sequence. J. Biochem. Mol. Biol. 40:1090-1094.
44. Zhu WL, Shin SY. 2009. Effects of dimerization of the cell-penetrating peptide Tat analog on antimicrobial activity and mechanism of bactericidal action. J. Pept. Sci. 15:345-352.
45. Zhu WL, Shin SY. 2009. Antimicrobial and cytolytic activities and plausible mode of bactericidal action of the cell penetrating peptide penetratin and its Lys-linked two-stranded peptide. Chem. Biol. Drug Des. 73:209-215.